23948sdkhjf

XINTELA AB

Novel marker technology in cell therapy and cancer

Xintela develops novel therapies in regenerative medicine and cancer based on its patented integrin marker technology platform. In regenerative medicine, Xintela’s current focus is to develop an allogeneic mesenchymal stem cell therapy for treatment of the degenerative joint disease osteoarthritis in horses and human. The cancer project aims to develop antibody-drug conjugates (ADCs) for first-in-class cancer therapy, with prime focus on the aggressive brain tumor glioblastoma.

 

Evy Lundgren Åkerlund "Xintela has taken big steps forward by building its own GMP facility for production of stem cells for clinical studies and by broadening the cancer therapy platform"

Leverantörstjänster

Fakta om XINTELA AB

Adress
XINTELA AB
MEDICON VILLAGE, Scheelevägen 8
223 81 Lund
Se på karta

Region
Sverige
Skåne län
Lunds kommun

Telefon: +46 46 275 75 00

VAT nummer: SE5567803480

Anställda: 12

Se hemsidan

Sänd till en kollega

1.208